Aylen Vanessa Ospina-Serrano, Virginia Abello-Polo, Orlando Bonell Patino-Escobar, Javier Ignacio Godoy-Barbosa, J. González, Henry Idrobo, Diego Emilio Lopera-Cortés, Humberto Martínez-Cordero, Mario Fernando Quintero-Ocaris, Javier Segovia-Gomez, C. A. Vargas-Baez, Andrés Yepes
IIn response to the Covid-19 pandemic, declared in March 2020 by the World Health Organization (WHO), the Colombian Association of Hematology and Oncology (ACHO) has been issuing communications aimed at providing guidance to health professionals involved in the treatment of hematological and oncological patients. Considering the pandemic mitigation phase we are currently facing, and the government’s approach to progressively tapering-off the quarantine, we deem it important to release a new update. These recommendations are not intended to impose a single conduct, since we understand that each case has particular characteristics and therefore it must be acted upon by individualizing each specific situation. The recommendations are based on documents issued by well-known cancer and hematological scientific associations, and are subject to change as more information becomes available.
{"title":"Recomendaciones para el cuidado de pacientes con cáncer y neoplasias hematológicas en el estado de pandemia COVID-19 en Colombia","authors":"Aylen Vanessa Ospina-Serrano, Virginia Abello-Polo, Orlando Bonell Patino-Escobar, Javier Ignacio Godoy-Barbosa, J. González, Henry Idrobo, Diego Emilio Lopera-Cortés, Humberto Martínez-Cordero, Mario Fernando Quintero-Ocaris, Javier Segovia-Gomez, C. A. Vargas-Baez, Andrés Yepes","doi":"10.35509/01239015.701","DOIUrl":"https://doi.org/10.35509/01239015.701","url":null,"abstract":"IIn response to the Covid-19 pandemic, declared in March 2020 by the World Health Organization (WHO), the Colombian Association of Hematology and Oncology (ACHO) has been issuing communications aimed at providing guidance to health professionals involved in the treatment of hematological and oncological patients. Considering the pandemic mitigation phase we are currently facing, and the government’s approach to progressively tapering-off the quarantine, we deem it important to release a new update. These recommendations are not intended to impose a single conduct, since we understand that each case has particular characteristics and therefore it must be acted upon by individualizing each specific situation. The recommendations are based on documents issued by well-known cancer and hematological scientific associations, and are subject to change as more information becomes available.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47692983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
En el año 2002 el grupo de Rosenberg en el Instituto Nacional de Cáncer en Estados Unidos demostró por primera vez que los linfocitos T pueden mediar regresiones tumorales notables, incluida la curación completa de pacientes con cáncer metastásico (1). Estos resultados logrados con la transferencia adoptiva de linfocitos T infiltrantes de tumor amplificados in vitro y luego restituidos al paciente, fue seguido de la implementación exitosa de terapias celulares con células CAR-T y el uso de anticuerpos anti-punto de control para el tratamiento de los tumores, con lo cual la Inmunoterapia junto a la Cirugía, la Quimioterapia y la Radioterapia se ha posicionado como el cuarto pilar de tratamiento del cáncer.
{"title":"La implementación de las vacunas basadas en neoantígenos tumorales: un desafío para la medicina de precisión en oncología","authors":"C. P. López","doi":"10.35509/01239015.713","DOIUrl":"https://doi.org/10.35509/01239015.713","url":null,"abstract":"En el año 2002 el grupo de Rosenberg en el Instituto Nacional de Cáncer en Estados Unidos demostró por primera vez que los linfocitos T pueden mediar regresiones tumorales notables, incluida la curación completa de pacientes con cáncer metastásico (1). Estos resultados logrados con la transferencia adoptiva de linfocitos T infiltrantes de tumor amplificados in vitro y luego restituidos al paciente, fue seguido de la implementación exitosa de terapias celulares con células CAR-T y el uso de anticuerpos anti-punto de control para el tratamiento de los tumores, con lo cual la Inmunoterapia junto a la Cirugía, la Quimioterapia y la Radioterapia se ha posicionado como el cuarto pilar de tratamiento del cáncer.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43946708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fernando Herazo Maya, Ricardo Brugés Maya, Ana Lucia Hincapie Uribe, Ana María Carvajal Barrera, Aylen Vanessa Ospina Serrano, Carlos Alberto Restrepo Ramirez, Carolina Benavides Duque, C. Alvarez, David Ignacio Gómez Duque, Jose Joaquin Caicedo Mallarino, Iván Andrés Bobadilla Arévalo, Jairo H. Patiño Pacheco, J. Cuello López, Johanna Paola Ibarra Palacio, John Jairo Sánchez Blando, Jorge Armando Egurrola Pedraza, Lina María Torres Vásquez, Luis Eduardo Viaña González, Luis Hernán Guzmán Abi-Saab, Luis José Palacios Fuenmayor, Luis Javier Gallon Villegas, Mauricio Lema Medina, Michel Hernández Restrepo, Natalia Jaramillo Botero, Néstor Llinás Quintero, Ray Manneh Kopp
The COVID-19 pandemic has given rise to an extraordinary and unprecedented crisis in health services, challenging the routine management of patients with breast disease. The main purpose of the following recommendations is to determine temporary prioritization schemes in the care route of these patients throughout the COVID-19 pandemic in Colombia. These recommendations are aimed at medical personnel and other health professionals involved in managing patients with breast disease, and to oncological IPS and members of the General System for Social and Health Security in Colombia. The recommendations issued are based on those published by the American College of Surgeons (ACS), and were adapted by a group of experts from ACM (The Colombian Mastology Association) and AMA (the Antioquia Mastology Association) with permission from the ACS. Adjustment suggestions were received from ACHO, ACRO and ACR representatives (Colombian Association of Hemato-Oncology - Colombian Association of Oncological Radiotherapy, and Colombian Association of Radiology, respectively). Three severity phases of the Covid-19 pandemic in the Colombian territory are proposed, along with recommendations for performing diagnostic images, outpatient consultation, surgery, systemic management, and radiotherapy, depending on the severity phases. These recommendations do not void or replace individual medical judgment, or national, regional, or institutional health policies. They aim to stimulate interdisciplinary approaches and adaptability and are subject to changes and updates according to new available evidence and the dynamic behavior of the pandemic.
{"title":"Recomendaciones para el diagnóstico, tratamiento y seguimiento del cáncer de mama durante la pandemia de SARS-Cov-2/COVID-19 en Colombia","authors":"Fernando Herazo Maya, Ricardo Brugés Maya, Ana Lucia Hincapie Uribe, Ana María Carvajal Barrera, Aylen Vanessa Ospina Serrano, Carlos Alberto Restrepo Ramirez, Carolina Benavides Duque, C. Alvarez, David Ignacio Gómez Duque, Jose Joaquin Caicedo Mallarino, Iván Andrés Bobadilla Arévalo, Jairo H. Patiño Pacheco, J. Cuello López, Johanna Paola Ibarra Palacio, John Jairo Sánchez Blando, Jorge Armando Egurrola Pedraza, Lina María Torres Vásquez, Luis Eduardo Viaña González, Luis Hernán Guzmán Abi-Saab, Luis José Palacios Fuenmayor, Luis Javier Gallon Villegas, Mauricio Lema Medina, Michel Hernández Restrepo, Natalia Jaramillo Botero, Néstor Llinás Quintero, Ray Manneh Kopp","doi":"10.35509/01239015.687","DOIUrl":"https://doi.org/10.35509/01239015.687","url":null,"abstract":"The COVID-19 pandemic has given rise to an extraordinary and unprecedented crisis in health services, challenging the routine management of patients with breast disease. The main purpose of the following recommendations is to determine temporary prioritization schemes in the care route of these patients throughout the COVID-19 pandemic in Colombia. \u0000These recommendations are aimed at medical personnel and other health professionals involved in managing patients with breast disease, and to oncological IPS and members of the General System for Social and Health Security in Colombia. The recommendations issued are based on those published by the American College of Surgeons (ACS), and were adapted by a group of experts from ACM (The Colombian Mastology Association) and AMA (the Antioquia Mastology Association) with permission from the ACS. Adjustment suggestions were received from ACHO, ACRO and ACR representatives (Colombian Association of Hemato-Oncology - Colombian Association of Oncological Radiotherapy, and Colombian Association of Radiology, respectively). Three severity phases of the Covid-19 pandemic in the Colombian territory are proposed, along with recommendations for performing diagnostic images, outpatient consultation, surgery, systemic management, and radiotherapy, depending on the severity phases. \u0000These recommendations do not void or replace individual medical judgment, or national, regional, or institutional health policies. They aim to stimulate interdisciplinary approaches and adaptability and are subject to changes and updates according to new available evidence and the dynamic behavior of the pandemic.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49153687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Perdomo, Lorena Montealegre-Páez, Rafael Adrián Pacheco-Orozco, Héctor Martínez-Gregorio, Felipe Vaca-Paniagua, J. Ardila, Federico Cayol, J. Oliver, C. Frecha, Javier Cuello López, David Carreño
ABSTRACT In recent years, the study of circulating nucleic acids has made great progress in the field of oncology, allowing for significant advances in clinical applications of liquid biopsy in diverse areas such as prognosis, staging, recurrence prediction, selection and monitoring of treatments, among others. This advance is largely due to the development of new and better technologies, some of which have even been validated for the diagnosis and clinical follow-up of certain types of cancer. However, the use of liquid biopsy as an additional tool in clinical oncology remains under study. Given the worldwide importance of this technological advance, a literature review was conducted to establish the current status of the use of liquid biopsy in oncology, as well as its current clinical applications, with a particular focus on Latin America.
{"title":"La biopsia líquida en el diagnóstico y monitoreo de pacientes oncológicos: oportunidades y retos en Latinoamérica","authors":"S. Perdomo, Lorena Montealegre-Páez, Rafael Adrián Pacheco-Orozco, Héctor Martínez-Gregorio, Felipe Vaca-Paniagua, J. Ardila, Federico Cayol, J. Oliver, C. Frecha, Javier Cuello López, David Carreño","doi":"10.35509/01239015.44","DOIUrl":"https://doi.org/10.35509/01239015.44","url":null,"abstract":"ABSTRACT \u0000 \u0000In recent years, the study of circulating nucleic acids has made great progress in the field of oncology, allowing for significant advances in clinical applications of liquid biopsy in diverse areas such as prognosis, staging, recurrence prediction, selection and monitoring of treatments, among others. This advance is largely due to the development of new and better technologies, some of which have even been validated for the diagnosis and clinical follow-up of certain types of cancer. However, the use of liquid biopsy as an additional tool in clinical oncology remains under study. Given the worldwide importance of this technological advance, a literature review was conducted to establish the current status of the use of liquid biopsy in oncology, as well as its current clinical applications, with a particular focus on Latin America.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45465149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. M. Sanz, Miurkis Endis, F. Llanos, John Chimbo, Xavier Abril, Francisco Faican, A. Vintimilla
ABSTRACT Hepatoblastoma is a malignant tumor. Surgical resection is the goal of treatment. A 7-month-old female patient with a hepatic mass in segments IV A and B, V, and VIII, classified as PRETEXT III. A central hepatectomy preserving segments VI, VII, II, and III, and a double biliodigestive derivation were performed. The right portal vein involved was ligated to produce a compensatory hyperplasia of the left liver, retaining the right one as an auxiliary. At 14 days, the left liver had increased by 48.1%. As an alternative to transplantation, central hepatectomy was combined with ligation of the right portal vein in a single surgical time.
{"title":"Hepatectomía central combinada con ligadura de la vena porta derecha en un niño con hepatoblastoma bilobar: reporte de un caso","authors":"L. M. Sanz, Miurkis Endis, F. Llanos, John Chimbo, Xavier Abril, Francisco Faican, A. Vintimilla","doi":"10.35509/01239015.468","DOIUrl":"https://doi.org/10.35509/01239015.468","url":null,"abstract":"ABSTRACT \u0000Hepatoblastoma is a malignant tumor. Surgical resection is the goal of treatment. A 7-month-old female patient with a hepatic mass in segments IV A and B, V, and VIII, classified as PRETEXT III. A central hepatectomy preserving segments VI, VII, II, and III, and a double biliodigestive derivation were performed. The right portal vein involved was ligated to produce a compensatory hyperplasia of the left liver, retaining the right one as an auxiliary. At 14 days, the left liver had increased by 48.1%. As an alternative to transplantation, central hepatectomy was combined with ligation of the right portal vein in a single surgical time.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49466427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABSTRACT Lip carcinoma is one of the most common malignancies in the head and neck region. Squamous-cell carcinoma is the most frequent type of histological cell carcinoma, chiefly affecting the lower lip. Different techniques for reconstructing defects of the lower lip after neoplasia resection are used; however, preserving the functionality and aesthetics of this area poses a challenge due to the anatomical position that causes accumulation of saliva, thus delaying the healing process. We present a total lower lip reconstruction extended towards the chin by using the Burow’s triangle, significantly improving functional and aesthetic results.
{"title":"Modificación de la técnica de Bernard-Burow en la reconstrucción total del labio inferior: presentación de un caso","authors":"Enrique Alonso Chaparro Aranguren","doi":"10.35509/01239015.355","DOIUrl":"https://doi.org/10.35509/01239015.355","url":null,"abstract":"ABSTRACT \u0000Lip carcinoma is one of the most common malignancies in the head and neck region. Squamous-cell carcinoma is the most frequent type of histological cell carcinoma, chiefly affecting the lower lip. Different techniques for reconstructing defects of the lower lip after neoplasia resection are used; however, preserving the functionality and aesthetics of this area poses a challenge due to the anatomical position that causes accumulation of saliva, thus delaying the healing process. We present a total lower lip reconstruction extended towards the chin by using the Burow’s triangle, significantly improving functional and aesthetic results.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41856198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adriana Jimenez Cotes, Jose Alejandro Esguerra Cantillo, Rosalba Ospino Peña, Laura Morales Ramirez, M. Gomez, Holman Ballesteros, G. González, Jorge Rugeles
Introducción: En el 2018 el cáncer de próstata presentó el segundo lugar en incidencia a nivel mundial (1). Con el avance en la tecnología y la aparición de la radioterapia de intensidad modulada (IMRT), se ha logrado disminuir dosis a tejido sano sin reducir la cobertura del volumen objetivo, permitiendo menor morbilidad asociada por la radioterapia y la posibilidad de escalar la dosis del tratamiento. El objetivo del estudio fue mostrar los resultados en supervivencia global y supervivencia libre de recaída bioquímica en el Instituto Nacional de Cancerología (INC) en los paciente diagnosticados con cáncer de próstata tratados con radioterapia de intensidad modulada (IMRT). Materiales y métodos: la revisión retrospectiva incluyó 98 pacientes, mayores de 40 años con cáncer de próstata, sin evidencia de enfermedad metastásica, tratados con IMRT entre 2008 - 2015, independiente de la supresión androgénica. La dosis administrada de radioterapia varió según su riesgo basado en la clasificación D´Amico. Hallazgos: La mediana de edad fue de 68,5 años, dentro de los cuales 16 pacientes (16%) se catalogaron de bajo riesgo, 33 (34%) de riesgo intermedio y 49 (50 %) de riesgo alto. La dosis media de radioterapia recibida fue de 75,8 Gy. La supervivencia libre de recaída bioquímica a 5 años fue del 78,6 % y la supervivencia global fue 98 %. Conclusión: Se obtuvo una supervivencia global y una supervivencia libre de recaída bioquímica a 5 años del 98% y 73,1% respectivamente.
{"title":"Supervivencia global y supervivencia libre de recaída bioquímica en pacientes con cáncer de próstata tratados con radioterapia de intensidad modulada (IMRT) en el Instituto Nacional de Cancerología","authors":"Adriana Jimenez Cotes, Jose Alejandro Esguerra Cantillo, Rosalba Ospino Peña, Laura Morales Ramirez, M. Gomez, Holman Ballesteros, G. González, Jorge Rugeles","doi":"10.35509/01239015.6","DOIUrl":"https://doi.org/10.35509/01239015.6","url":null,"abstract":"Introducción: En el 2018 el cáncer de próstata presentó el segundo lugar en incidencia a nivel mundial (1). Con el avance en la tecnología y la aparición de la radioterapia de intensidad modulada (IMRT), se ha logrado disminuir dosis a tejido sano sin reducir la cobertura del volumen objetivo, permitiendo menor morbilidad asociada por la radioterapia y la posibilidad de escalar la dosis del tratamiento. El objetivo del estudio fue mostrar los resultados en supervivencia global y supervivencia libre de recaída bioquímica en el Instituto Nacional de Cancerología (INC) en los paciente diagnosticados con cáncer de próstata tratados con radioterapia de intensidad modulada (IMRT). \u0000Materiales y métodos: la revisión retrospectiva incluyó 98 pacientes, mayores de 40 años con cáncer de próstata, sin evidencia de enfermedad metastásica, tratados con IMRT entre 2008 - 2015, independiente de la supresión androgénica. La dosis administrada de radioterapia varió según su riesgo basado en la clasificación D´Amico. \u0000Hallazgos: La mediana de edad fue de 68,5 años, dentro de los cuales 16 pacientes (16%) se catalogaron de bajo riesgo, 33 (34%) de riesgo intermedio y 49 (50 %) de riesgo alto. La dosis media de radioterapia recibida fue de 75,8 Gy. La supervivencia libre de recaída bioquímica a 5 años fue del 78,6 % y la supervivencia global fue 98 %. \u0000Conclusión: Se obtuvo una supervivencia global y una supervivencia libre de recaída bioquímica a 5 años del 98% y 73,1% respectivamente.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43650748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Johana Andrea Lineros-Hurtado, Pilar Romero-Romero, Yuly Milena Salgado-Lerma, Carolina Wiesner-Ceballos
The development and innovation of new technologies has improved the detection of high-risk human papillomavirus infection. Hybrid capture II is an assay that is based on hybridization and chemiluminescence. Cobas HPV Test is a qualitative PCR and Aptima HPV Assay allows to detect the expression of messenger RNA of the high-risk HPV E6 / E7 oncoproteins. These techniques have advantages, in comparison, with conventional cytology that is routinely used for the detection of cervical cancer. In the ESTAMPA study, 13,691 prosecutions were carried out that allowed to identify that for the planning of research projects or for the implementation of HPV screening tests, it is necessary to analyze the advantages and disadvantages of market tests.
{"title":"Características operativas de técnicas moleculares empleadas para la detección del virus del papiloma humano en el proyecto ESTAMPA","authors":"Johana Andrea Lineros-Hurtado, Pilar Romero-Romero, Yuly Milena Salgado-Lerma, Carolina Wiesner-Ceballos","doi":"10.35509/01239015.106","DOIUrl":"https://doi.org/10.35509/01239015.106","url":null,"abstract":"The development and innovation of new technologies has improved the detection of high-risk human papillomavirus infection. Hybrid capture II is an assay that is based on hybridization and chemiluminescence. Cobas HPV Test is a qualitative PCR and Aptima HPV Assay allows to detect the expression of messenger RNA of the high-risk HPV E6 / E7 oncoproteins. These techniques have advantages, in comparison, with conventional cytology that is routinely used for the detection of cervical cancer. In the ESTAMPA study, 13,691 prosecutions were carried out that allowed to identify that for the planning of research projects or for the implementation of HPV screening tests, it is necessary to analyze the advantages and disadvantages of market tests.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48230984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Es difícil expresar los sentimientos ante la pérdida de un colega y amigo que fue parte del Instituto Nacional de Cancerología (INC) y un gran líder clínico en el campo de la mastología a nivel nacional. El Dr. José Fernando Robledo realizó sus estudios de cirugía general, cirugía de mama y de tejidos blandos en el INC desde 1983 hasta 1989 donde entró a formar parte del Grupo de mama y tejidos blandos.
{"title":"In memoriam Jose Fernando Robledo","authors":"C. Duarte","doi":"10.35509/01239015.721","DOIUrl":"https://doi.org/10.35509/01239015.721","url":null,"abstract":"Es difícil expresar los sentimientos ante la pérdida de un colega y amigo que fue parte del Instituto Nacional de Cancerología (INC) y un gran líder clínico en el campo de la mastología a nivel nacional. El Dr. José Fernando Robledo realizó sus estudios de cirugía general, cirugía de mama y de tejidos blandos en el INC desde 1983 hasta 1989 donde entró a formar parte del Grupo de mama y tejidos blandos.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43932132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
La disminucion de la mortalidad por Cancer de Mama, demostrada en algunos paises del mundo, se ha conseguido gracias a la administracion de tratamientos oportunos e integrales y posiblemente a una estrategia de tamizacion formal que incluya a la mamografia como eje principal. La funcion principal de la mamografia de tamizacion es el diagnostico temprano de la enfermedad para lograr reducir la mortalidad por esta causa. La implementacion de estrategias de deteccion temprana en cancer de mama, en Colombia, intenta ejecutarse bajo importantes limitaciones y logisticas de nuestro sistema de salud. Estas estrategias se han venido construyendo de la mano de centros de tratamiento oncologico integral como el INC, asociaciones cientificas y la experiencia de cientos de medicos especialistas en el manejo de dicha enfermedad.
{"title":"Retos para el control del cáncer en Colombia: ante todo más acción.","authors":"L. Gonzalez","doi":"10.35509/01239015.712","DOIUrl":"https://doi.org/10.35509/01239015.712","url":null,"abstract":"La disminucion de la mortalidad por Cancer de Mama, demostrada en algunos paises del mundo, se ha conseguido gracias a la administracion de tratamientos oportunos e integrales y posiblemente a una estrategia de tamizacion formal que incluya a la mamografia como eje principal. La funcion principal de la mamografia de tamizacion es el diagnostico temprano de la enfermedad para lograr reducir la mortalidad por esta causa. \u0000La implementacion de estrategias de deteccion temprana en cancer de mama, en Colombia, intenta ejecutarse bajo importantes limitaciones y logisticas de nuestro sistema de salud. Estas estrategias se han venido construyendo de la mano de centros de tratamiento oncologico integral como el INC, asociaciones cientificas y la experiencia de cientos de medicos especialistas en el manejo de dicha enfermedad.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48398806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：